Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Theravir Management L.p.

Charles S Irving

Zichria Zakay-Rones

Amos Panet

Eithan Galun

Evgeniya Greenbaum

Arnold I Freeman

Linda Rasooly

The present invention discloses methods for inducing regression of a tumor in a subject by administering a pharmaceutical composition comprising a lentogenic strain of Newcastle disease virus (NDV). A preferred viral strain of NDV for inducing regression of a tumor in a subject is a clonal strain of NDV, the NDV HUJ. The methods of the present invention are particularly useful for inducing regression of tumors in patients unresponsive to conventional anti-cancer therapies.

Compositions of NDV and methods of use thereof for treatment of cancer

The present invention discloses lentogenic viral strains useful in the treatment of cancer. A preferred viral strain of Newcastle Disease Virus (NDV) is specifically characterized in terms of biological activities. The present invention further discloses treatment of cancer by application of a clonal NDV strain to tumors. Another feature of the invention is the use of at least one isolated viral glycoprotein or a subunit or analog thereof or of an isolated polynucleotide encoding the same for the treatment of cancer.

Compositions and methods for treatment of cancer

Growing community of inventors

Caesarea, Israel

Charles S Irving